Web Exclusives

Long-term results of a pivotal trial of acalabrutinib verify that it is effective and safe as first-line therapy for patients with chronic lymphocytic leukemia. Read More ›

According to findings from a large clinical trial, the combination of ibrutinib and ublituximab is effective in treating patients with chronic lymphocytic leukemia. Read More ›

The ASCEND trial confirmed that acalabrutinib, a next-generation targeted treatment, is more effective than traditional chemoimmunotherapy in patients with relapsed chronic lymphocytic leukemia. Read More ›

Recently reported data show that fixed-duration treatment with venetoclax and obinutuzumab for 12 months is effective and tolerable in some patients with chronic lymphocytic leukemia. Read More ›

Patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who require systemic therapy have a new chemotherapy-free combination regimen to consider. Read More ›

The chemotherapy-free combination of venetoclax plus obinutuzumab has shown efficacy and tolerability in older patients with chronic lymphocytic leukemia. Adding acalabrutinib, a new targeted agent, may enhance the clinical benefits of this regimen, according to results of a clinical trial. Read More ›

Cancer specialists are now able to use a new scoring system to decide when to start treatment for patients who have been diagnosed with chronic lymphocytic leukemia. Read More ›

Alliance A041702 is a large clinical trial that is exploring whether adding venetoclax to the combination of ibrutinib and obinutuzumab can improve outcomes in patients with chronic lymphocytic leukemia. Read More ›

According to results from a recent study, patients with chronic lymphocytic leukemia are more likely to survive for longer time periods if their posttreatment tests show no evidence of residual disease. Read More ›